William Blair Brokers Lower Earnings Estimates for ELAN

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities research analysts at William Blair cut their Q4 2025 earnings per share estimates for Elanco Animal Health in a report released on Thursday, November 7th. William Blair analyst B. Vazquez now expects that the company will post earnings of $0.18 per share for the quarter, down from their prior estimate of $0.19. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.92 per share. William Blair also issued estimates for Elanco Animal Health’s Q3 2026 earnings at $0.17 EPS and FY2026 earnings at $1.05 EPS.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.91% and a net margin of 4.60%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the business posted $0.18 earnings per share. The business’s revenue was down 3.6% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on ELAN. Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Stifel Nicolaus restated a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $17.14.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $14.12 on Monday. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. The firm has a market cap of $6.98 billion, a PE ratio of 35.30, a price-to-earnings-growth ratio of 1.47 and a beta of 1.41. Elanco Animal Health has a 12 month low of $10.42 and a 12 month high of $18.80. The company’s 50-day moving average price is $13.88 and its two-hundred day moving average price is $14.76.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors have recently modified their holdings of ELAN. Benjamin F. Edwards & Company Inc. boosted its stake in Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC bought a new position in shares of Elanco Animal Health in the 3rd quarter worth $29,000. nVerses Capital LLC bought a new stake in Elanco Animal Health in the second quarter valued at about $32,000. ORG Partners LLC acquired a new position in Elanco Animal Health in the second quarter valued at about $31,000. Finally, AM Squared Ltd acquired a new position in Elanco Animal Health in the third quarter valued at about $34,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.